These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33728870)

  • 1. Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view.
    Ceccarelli F; Botticelli A; Natalucci F; Olivieri G; Cirillo A; Alessandri C; Marchetti P; Conti F
    Clin Transl Oncol; 2021 Sep; 23(9):1961-1962. PubMed ID: 33728870
    [No Abstract]   [Full Text] [Related]  

  • 2. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.
    Fujimura T; Lyu C; Tsukada A; Sato Y; Kambayashi Y; Aiba S
    J Dermatol; 2019 May; 46(5):e177-e178. PubMed ID: 30353913
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.
    Saleh K; Bellanger C; Garcia G; Classe M; Even C
    Eur J Cancer; 2021 Mar; 145():155-157. PubMed ID: 33476895
    [No Abstract]   [Full Text] [Related]  

  • 4. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
    Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
    Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
    [No Abstract]   [Full Text] [Related]  

  • 5. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
    Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
    Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
    BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].
    Reich M; Coutzac C
    Bull Cancer; 2021 Mar; 108(3):228-229. PubMed ID: 33531154
    [No Abstract]   [Full Text] [Related]  

  • 9. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
    Azari AE; Stratton R; Singh A
    Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
    [No Abstract]   [Full Text] [Related]  

  • 12. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.
    Gracia-Cazaña T; Padgett E; Calderero V; Oncins R
    Dermatol Online J; 2021 Mar; 27(3):. PubMed ID: 33865285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology.
    Tabata MM; Choi S; Hirotsu K; Kwong B; Soleymani T
    J Am Acad Dermatol; 2020 Apr; 82(4):986-994. PubMed ID: 31437546
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
    Simonsen AB; Kaae J; Ellebaek E; Svane IM; Zachariae C
    J Am Acad Dermatol; 2020 Nov; 83(5):1415-1424. PubMed ID: 32320766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
    Miyauchi M; Toyoda M; Zhang J; Hamada N; Yamawaki T; Tanaka J; Harada K; Kashizaki F; Fukagawa M
    J Diabetes Investig; 2020 May; 11(3):748-749. PubMed ID: 31587459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].
    Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H
    Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genital lichen sclerosus after nivolumab.
    Miraglia E; Soda G; Giustini S
    Dermatol Online J; 2020 Nov; 26(11):. PubMed ID: 33342187
    [No Abstract]   [Full Text] [Related]  

  • 19. An update on the safety of nivolumab for the treatment of advanced melanoma.
    Czarnecka AM; Rutkowski P
    Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935
    [No Abstract]   [Full Text] [Related]  

  • 20. Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancer.
    Lee H; Chung JH; Jo SJ
    Int J Dermatol; 2020 Jun; 59(6):685-686. PubMed ID: 31782147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.